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Human herpesvirus 6 (HHV-6) is the only human herpesvirus encoding U94/rep, homologue to the parvovirus non-structural gene rep68/78.
Results to date suggest that HHV-6 U94/rep might regulate viral gene expression and have a role in viral latency. To determine the effect of U94/
REP upon viral replication, the protein was produced. The purified U94/REP retained the characteristic immunological features. It was
internalized and localized in the nucleus of human cells, showing marked inhibitory activity on the replication of HHV-6 (both variants A and B).
The effect of U94/REP was dose-dependent and sensitive to treatment with single-stranded but not double-stranded DNA. U94/REP inhibited the
replication of other betaherpesviruses, HHV-7 and human cytomegalovirus, but had no effect on herpes simplex virus. These results confirm the
action of U94/rep latency gene in the regulation of HHV-6 replication with implications for co-reactivations and latency of human
betaherpesviruses.
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Human herpesvirus 6 (HHV-6) is a member of the
betaherpesvirus subfamily, it is closely related to human
herpesvirus 7 (HHV-7) and more distantly to human cytomeg-
alovirus (HCMV; Dominguez et al., 1999; Gompels et al.,
1995; Salahuddin et al., 1986). Primary infection occurs in the
early childhood and causes exanthem subitum and febrile
illness (Hall et al., 1994; Yamanishi et al., 1988). Thereafter,
HHV-6 establishes a latent infection, where it is tightly
controlled, but can reactivate during immunosuppression,
establishing severe diseases in immunodeficient individuals
including transplant and HIV/AIDS patients (Carrigan and0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: ddl@unife.it (D. Di Luca).Knox, 1994; Drobyski et al., 1993a; Gompels, 2004; Lusso and
Gallo, 1995). HHV-6 has been associated to thrombotic
microangiopathy (Matsuda et al., 1999), encephalitis and
meningo-encephalitis (Ishiguro et al., 1990), infectious mono-
nucleosis (Steeper et al., 1990), persistent lymphadenopathy
(Niederman et al., 1988), autoimmune disorders (Krueger et al.,
1991), AIDS dementia (Knox and Carrigan, 1995; Lusso and
Gallo, 1995) and to complications following solid organ and
bone marrow transplantation, such as pneumonitis and graft
rejection (Carrigan and Knox, 1994; Drobyski et al., 1993b;
Ljungman, 2002; Razonable and Paya, 2002), as well as fatal
encephalitis in bone marrow and stem-cell-transplanted
patients (Rapaport et al., 2002; Zerr et al., 2002). Recent
studies also point to more severe pathology, FCMV disease_ in
betaherpesvirus co-reactivations in solid organ transplantation
(Emery, 2001; Lautenschlager et al., 2002) as well as a possible
link to multiple sclerosis (Cermelli et al., 2003; Chapenko et6) 402 – 414
www.e
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Simon et al., 2002). Thus, factors regulating latent infection
have important implications for HHV-6-associated pathology.
HHV-6 strains are divided in two variants: HHV-6A and
HHV-6B, which share a substantial degree of homology, but
might differ for cell tropism and pathological implications
(Campadelli-Fiume et al., 1999; Clark, 2000; Gompels, 2004).
HHV-6 DNA shows a typical betaherpesvirus genomic
organization and encodes several genes that are conserved in
all human herpesviruses (Gompels et al., 1995). A unique
genomic characteristic of HHV-6 consists in the presence of
ORF U94/rep, a gene encoded by both variants but absent in all
other human herpesviruses, even in the closer related betaher-
pesviruses, HHV-7 and HCMV. Several studies suggest that
U94/rep may have features of an HHV-6 specific Flatency_
gene (Rotola et al., 1998; Turner et al., 2002; Yoshikawa et al.,
2003). ORF U94/rep encodes a 490-amino-acid protein, highly
conserved between HHV-6 A and B variants (Rapp et al.,
2000). Interestingly, it is homologous to rep68/78, encoded by
the human parvovirus adeno-associated virus type 2 (AAV-2), a
DNA virus unrelated to HHV-6 (Thomson et al., 1991). The
presence of U94/rep is unique among human herpesviruses,
and only rat cytomegalovirus (RCMV) encodes a rep homo-
logue, r127 rep (Vink et al., 2000), suggesting either a common
betaherpesvirus ancestor or independent acquisitions as her-
pesviruses can act as helper virus for AAV.
AAV-2 rep gene product (REP) is a non-structural protein
involved in several aspects of AAV-2 regulation of gene
expression, including DNA binding, site- and strand-specific
endonuclease, helicase and ATPase activities (Im and
Muzyczka, 1990, 1992). The presence of an intact rep gene
is necessary for the integration of AAV DNA within defined
regions of the cellular genome (Linden et al., 1996a, 1996b). In
addition, AAV-2 REP inhibits transcription from HIV-1 long
terminal repeat (LTR) promoter in fibroblasts and T-cell lines
(Oelze et al., 1994) and represses the expression of cellular
oncogenes (Chiorini et al., 1996; Surosky et al., 1997).
HHV-6 U94/rep gene product shares 24% identity with
AAV-2 REP at the amino-acid level, suggesting that it may
possess a similar range of functions in viral replication and
survival within the infected host. This hypothesis is confirmed
by the observation that HHV-6 U94/rep complements the
replication of rep-deficient AAV-2 genome (Thomson et al.,
1994). The U94/rep transcript is expressed at low levels during
‘‘in vitro’’ infection, suggesting that only small amounts of
protein are required during productive viral replication or that it
plays a primary role during latency (Rapp et al., 2000).
Interestingly, U94/rep transcript is detected in ‘‘in vivo’’
latently infected peripheral blood mononuclear cells from
healthy donors, in the absence of other viral mRNAs expressed
during productive infection (Rotola et al., 1998; Yoshikawa et
al., 2003). Furthermore, in vitro studies show that it might be
involved in viral transcription and replication. U94/rep binds
the human transcriptional factor TBP (Mori et al., 2000), binds
ssDNA (unlike RCMV rep which binds also dsDNA;
Dhepakson et al., 2002), inhibits transcription from HIV-1
LTR in T cell lines (Araujo et al., 1995) and suppressestransformation by H-ras (Araujo et al., 1995). In addition, T
cell lines stably transformed with U94/rep are not permissive to
HHV-6 lytic infection and inhibit HHV-6 origin of DNA
replication in transient amplicon replication assays (Rotola et
al., 1998; Turner et al., 2002). These results suggest that U94/
rep might have a crucial role in the regulation of viral gene
expression and replication and be important for the mainte-
nance of viral latency.
However, the role of U94/REP in viral replication is not
well documented due to the low yields of native protein from
HHV-6-infected cells (Rapp et al., 2000) and to the difficulties
in purifying a recombinant U94/REP protein. These problems
have been circumvented by transfecting the U94/rep gene
(Rapp et al., 2000; Rotola et al., 1998; Thomson et al., 1994;
Turner et al., 2002) or by production of fusion proteins (Mori et
al., 2000), but the availability of a purified U94/REP protein is
a necessary requisite to characterize directly biological func-
tions and to determine antigenic reactivity.
We therefore undertook the task of producing and purifying
a recombinant U94/REP protein and to carry out functional
studies. We succeeded in obtaining a >95% pure protein, which
retained immunologic reactivity (Caselli et al., 2002). We show
that the recombinant U94/REP protein inhibits the production
of HHV-6 (both variant A and B) in infected T cells with a
dose-dependent effect, confirming that it plays an important
role in the replication cycle and could be a critical component
in regulation of latency. Interestingly, U94/REP inhibits also
other betaherpesviruses, HHV-7 replication in T cells and
HCMV production in human fibroblasts, but has no effect on
the alphaherpesvirus, herpes simplex virus (HSV) replication.
Furthermore, we show that the mechanism of replication
inhibition correlates with its ability to interact with single-
stranded but not double-stranded DNA consistent with
previous reports demonstrating U94/REP has a single-stranded
DNA-binding protein (Dhepakson et al., 2002).
Results
Production and purification of the U94/REP protein
The full-length U94/rep gene (nucleotides 141,394 to
142,866) was excised by HindIII digestion from plasmid
pSR2PH (Rotola et al., 1998) and cloned under the transcrip-
tional control of the T5/lac promoter, obtaining the recombi-
nant pQE-rep plasmid. The recombinant plasmid was
transfected in M15 strain of E. coli host cells, and bacterial
clones were selected after sequencing the insert to ensure that
the correct coding sequence had been cloned in the plasmid
vector. Following 1, 3 or 5 h of induction with 2 mM IPTG,
samples were collected and analyzed by SDS-PAGE. The
results showed that a protein with the predicted molecular
weight of 56 kDa was expressed after 5 h of induction in pQE-
rep transformed cells (Fig. 1A) and formed approximately 5%
of the total bacterial proteins, as estimated by densitometric
reading. The 56 kDa band was not present in the non-induced
pQE-rep bacteria, as well as in the mock extract from bacteria
containing only pQE vector sequences (not shown). The
Fig. 1. Production and purification of U94/REP protein under denaturing conditions. (A) pQE-rep transformed M15 host cells were uninduced (U) or induced (I) with
2 mM IPTG for 5 h and analyzed by SDS-PAGE. The 56 kDa protein obtained in the insoluble fraction was then purified by ion exchange chromatography, as
described in Materials and methods and subsequently analyzed by SDS-PAGE. Purification of the protein fragments of 29.8 and 35.8 kDa, corresponding to the
carboxy-(RC) and amino-terminal (RN) regions of U94/REP is also shown. (B) Western blot assays were performed using a 1:200 dilution of pre-immune or immune
rabbit serum, obtained by injection of pSR2pH plasmid as described in Materials and methods, and 5 Ag/lane of crude recombinant U94/REP (R), purified U94/REP
(Rp) or mock (M) as the antigens. (C) Western blot assays were performed as described for panel B, with 5 Ag/lane of recombinant U94/REP (R), amino- or carboxy-
terminal RepN or RepC subfragments (RN, RC) or mock (M) as the antigens.
Fig. 2. Uptake and cellular localization of U94/REP protein. IFA analysis of treated J-Jhan cells was performed using mAb directed against the 6-His sequence
located at the amino-terminus of the recombinant protein. Results refer to 24 and 72 h of incubation with 2 Ag/ml of U94/REP protein.
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suggesting that it accumulated in bacterial inclusion bodies.
To solubilize the crude U94/REP preparation, cell pellets were
treated with lysis buffers containing increasing molar con-
centrations of urea. Complete solubilization of the crude U94/
REP protein was achieved with 6 M urea. Therefore,
purification of U94/REP was attempted by chromatography
under denaturing conditions. The urea-solubilized protein was
dialyzed to eliminate residues of Triton detergent then applied
to a hydroxyapatite column and eluted with 500 mM
phosphate buffer, obtaining a >95% pure protein (Fig. 1A).
The yield of the purified protein was approximately 6 mg/
l culture, as measured after refolding and aqueous solubiliza-Fig. 3. Biological activity of recombinant U94/REP protein on HHV-6 variant A i
Materials and methods with HHV-6 variant A (strain U1102). Cell samples wer
Semiquantitative PCR amplification of HHV-6 DNA, from samples collected 21 da
extracted from cell samples (S) were amplified in the genomic region of HHV-6 U42
positive control (C+). The DNA extracted from uninfected cells was also used as the
Ag/ml of mock bacterial lysate, R1–R5 are HHV-6-infected cells in the presence of 1
6 replication, expressed as the maximum dilution which resulted positive for the pre
HHV-6 gp116 of uninfected (N.I.) and HHV-6-infected J-Jhan cells in the presence o
correspond to cell samples collected 21 days p.i. (D) Time course of the results of I
represents the mean of three different samples. (E) Time course of HHV-6 infection
(R*) infection.tion achieved by serial dialysis in decreasing concentrations of
urea. Also the amino (Aa 1–326) and carboxy (Aa 220–491)
termini of U94/REP were cloned and produced using the same
protocol (Fig. 1A).
Analysis of purified U94/REP proteins by Western blot assay
and ELISA
The identity of the bacterial recombinant protein was
confirmed by immunological assays. To this purpose, a
polyclonal antiserum reacting specifically with the native
HHV-6 U94/REP protein was obtained in rabbits by direct
DNA immunization using plasmid pSR2PH as the immunogen.nfection. Susceptible J-Jhan T cells were cultured and infected as described in
e collected at 1-week intervals and analyzed by semiquantitative PCR. (A)
ys post-infection. Serial ten-fold dilutions (1 to 6 lanes) of template DNA
. DNA from HHV-6A infected J-Jhan cells at full cytopathic effect was used as a
negative control (C). Mock shows HHV-6-infected cells in the presence of 5
, 2 or 5 Ag/ml of U94/REP protein. (B) The plot shows the time course of HHV-
sence of HHV-6A DNA. (C) Immunofluorescence with monoclonal antibody to
f mock lysate (Mock) or of 2 Ag/ml of U94/REP (U94/REP). The results shown
FA assay. Results are expressed as positive cells/total cells (%), and each value
of J-Jhan cells in the presence of 2 Ag/ml of U94/REP, added before (R) or after
Fig. 4. Biological activity of U94/REP protein on HHV-6 variant A infection
(A) J-Jhan cells were cultured and infected as described. Cell samples were
collected at 1-week intervals and analyzed by semiquantitative PCR of HHV-6
DNA, performing serial ten-fold dilutions (1 to 6) of template DNA. The
results show U42 amplification performed on the sample of day 21
corresponding to the peak of virus production, treated with 2 Ag/ml protein
Results are expressed as the maximum dilution which resulted positive for the
presence of HHV-6A DNA; control (C), U94/REP (R), heat denatured U94
REP (RD), U94/REP plus ssDNA (Rss), U94/REP plus dsDNA (Rds), RepN
amino-terminal region (RN), RepC carboxy-terminal region (RC). (B) Results o
SDS-PAGE analysis of eluate fractions after ssDNA or dsDNA-affinity column
chromatography performed as described in Materials and methods. (C) Time
course of HHV-6 replication in the presence of U94/REP (R), N-termina
domain (RN) and C-terminal domain (RC), expressed as the maximum dilution
which resulted positive for the presence of HHV-6A DNA.
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boosted subcutaneously and intradermally, obtaining specific
anti-U94/REP antisera.
The immunological reactivity of the recombinant proteins
was analyzed by Western blot (Fig. 1B). Proteins from induced
bacteria transformed either with pQE-rep or control pQE30
were separated by electrophoresis and transferred onto nitro-
cellulose filters. Blots were incubated with the polyclonal
rabbit antiserum raised against U94/rep DNA diluted 1:200 and
developed with the addition of chemiluminescent substrate.
The results show that the U94/REP fusion protein is
specifically recognized by the rabbit antiserum obtained by
DNA immunization, resulting in a specific reactive band absent
in the mock bacterial lysate and not reacting with pre-immune
rabbit serum (Fig. 1B). The purification procedure did not
modify the immuno-reactivity of the purified protein, as shown
by the presence of a single reactive band with the expected
molecular weight. The rabbit anti-U94/REP polyclonal antise-
rum specifically recognized also protein subfragments
corresponding to the amino- and carboxy-terminal regions of
U94/REP (RepN and RepC), resulting in reactive bands of 35.8
and 29.8 kDa respectively (Fig. 1C).
The U94/rep gene product obtained in bacteria reacted also
in ELISA, as shown by the reactivity observed with the
immune rabbit antiserum (OD492nm = 0.382) but not with the
pre-immune serum (OD492nm = 0.061). The specificity of
binding was further confirmed by absence of reactivity of
immune serum against mock coated plates (OD492nm = 0.048).
Analysis of U94/REP uptake and cellular localization
The ability of the recombinant protein to be internalized by
human cells was analyzed by IFA, using a mAb specifically
recognizing the stretch of histidines located at the amino-
terminus of the fusion protein. J-Jhan cells were cultured with
1, 2 or 5 Ag/ml of U94/REP and analyzed 24 and 72 h later.
The results show that U94/REP was internalized by cells, as
indicated by a bright generalized cell staining after 24 h, and
accumulated in the cell nucleus at 72 h, indicating a specific
nuclear targeting of the protein (Fig. 2).
Analysis of U94/REP biological activity
To ascertain whether the recombinant protein produced in
E. coli, purified under denaturing conditions and refolded,
maintained biological activity, we analyzed its effect on HHV-
6A infection in T cell lines, based on the previous observation
that T cell clones transformed with U94/rep gene are resistant
to HHV-6 lytic infection (Rotola et al., 1998). Aliquots of
permissive J-Jhan cells were cultured in the presence of
different concentrations of refolded purified U94/REP or
mock lysate (control) and subsequently infected with a
standardized inoculum of HHV-6 A (strain U1102). The titer
of the purified cell-free viral stock was 103 TCID50/ml. Cells
infected with HHV-6 in the absence of U94/REP developed
cytopathic effect between day 3 and 7 and were completely
lysed between 14 and 21 days after infection. The relativelylong time to develop complete cell lysis is to be ascribed to
the low MOI, due to the low infectious titer of purified viral
stock. Cells infected in the presence of U94/REP developed
little or no cytopathic effect, and 4 weeks after infection, no
cell lysis was observed, with all concentrations of U94/REP.
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and rtPCR. The recombinant protein produced in bacteria
inhibited HHV-6 replication in J-Jhan-infected cells in a dose-
dependent manner, and both viral DNA and rates of
expression of viral functions were significantly decreased
(Figs. 3A–B). U94/REP-treated cells had viral DNA loads up
to 6 logs lower than control cells infected with HHV-6 in the
presence of mock bacterial lysate, as shown by semiquanti-
tative PCR analyses performed on U42 gene. Extinction of
the signal after amplification of h-actin occurred at the same
dilution for all samples (not shown), showing that the same
amount of material has been analyzed for all samples. Upon
removal of U94/REP from culture medium, cells returned
fully susceptible to HHV-6 infection within 48 h (not shown),
confirming that resistance to virus replication is associated to
the presence of U94/REP. Similar results were obtained
performing PCR analysis on different genomic regions (U31
and U94—data not shown) and by rtPCR, analyzing
transcripts from IE and E genes, respectively, U42 and U31
(not shown). No difference in the cellular growth rate andFig. 5. Biological activity of recombinant U94/REP protein upon HHV-6 variant B
infected as described in Materials and methods, respectively, with HHV-6 variant
intervals and analyzed by semiquantitative PCR and rtPCR. Mock results refer to 5
amounts used. (A and C) Semiquantitative PCR amplification of gene U42 for HHV-
from HHV-6B- or HHV-7-infected Sup T1 cells collected at complete cytopathic effe
6 lanes) of the DNA template extracted from sample cells (S). (B and D) The diag
positive for the presence and transcription respectively of HHV-6B and HHV-7.viability was observed between control cells and cells treated
with U94/REP, as shown by Trypan Blue cell counting at
different times p.i. and by analysis of cytotoxicity by MTT
assay (data not shown). The results were confirmed by IFA,
using a commercial mAb against gp116 (late antigen). As
shown in Figs. 3C–D, expression of virus antigens and
cytopathic effect was significantly inhibited in cells treated
with U94/REP compared to control mock-treated cells
infected with the same amount of virus, confirming that
U94/REP inhibits HHV-6 replication.
To determine whether U94/REP interferes with virus entry,
resulting in inefficient infection, or acts after adsorption,
inhibiting viral replication, U94/REP was added to HHV-6-
infected cells only after removal of the virus inoculum. Also in
this instance HHV-6 replication and yield were significantly
reduced (Fig. 3E). The degree of inhibition was similar to that
observed when infection takes place in the presence of U94/
REP, suggesting that the viral protein acts after virus entry.
To confirm specificity and investigate mode of action, HHV-
6 infection experiments were repeated using equal amounts of(A, B) and HHV-7 (C, D) infection of susceptible Sup T1 cells. Cells were
B (strain CV) or HHV-7 (strain CZ). Cell samples were collected at 1-week
Ag/ml of mock bacterial lysate; identical results were obtained with the other
6B and HHV-7, respectively. Positive controls (C+) were represented by cDNA
ct. Amplification reactions were performed by using 1:10 serial dilutions (1 to
rams summarize the results, expressed as the maximum dilution which resulted
E. Caselli et al. / Virology 346 (2006) 402–414408U94/REP either heat denatured or preincubated with ssDNA or
dsDNA or with the two amino- and carboxy-terminal RepN
and RepC protein subfragments. The results, summarized in
Fig. 4A, show that heat denaturation abolished U94/REP
activity upon HHV-6 replication, suggesting that the folding of
the protein is important for its action. One important molecular
characteristic of U94/REP is the ability to bind ssDNA and not
dsDNA, as originally described by Dhepakson et al. (2002).
This is distinct from rCMV rep which binds both ds and
ssDNA (van Cleef et al., 2004). Our preparation of U94/REP
retains this characteristic, binding ssDNA but not dsDNA (Fig.
4B). This DNA-binding activity is required for the U94/Rep
inhibition of replication since preincubation of the protein with
ssDNA, but not with dsDNA, neutralized the inhibitory activity
of U94/REP (Fig. 4A). The C-terminal domain showed no
inhibition of replication, further confirming specificity, whereas
the N-terminal domain (RepN) retained inhibitory activity (Fig.
4A), suggesting that the active domain is encoded by the 5Vend
of the gene. The activity of N-terminal domain, but not of C-
terminal, was shown also by time course experiments (Fig.
4C). Interestingly, only the N-terminal domain retained the
ability to bind ssDNA (Fig. 4B).
The activity of U94/REP was tested also on the distantly
related alphaherpesvirus, HSV, as well as the other human
betaherpesviruses: HHV-6 variant B (strain CV), HHV-7 (strain
CZ) and HCMV (Towne strain). Samples were collected and
analyzed as described in Materials and methods with MTT
assays performed on the cells treated with U94/REP to confirm
the absence of non-specific cytotoxic effects. While no
differences in virus production were shown in the presenceFig. 6. Biological activity of U94/REP protein upon HCMV infection on
permissive HEL cells. Cells were infected as described in Materials and
methods and collected at 5 days p.i. for IFA analysis, using anti-IE-1, anti-pp65
and anti-gB antibodies. Right column: untreated HEL cells infected with
HCMV (m.o.i. 0.05 PFU/cell). Left column: cell infected in the presence of
U94/REP (3 Ag/ml).or absence of U94/REP during HSV-1 (strain F) infections of
permissive Vero cells (not shown), there were marked effects
on the betaherpesviruses. Results of HHV-6B and HHV-7
infection analyses are summarized in Fig. 5 and show that U94/
REP inhibits with a dose-dependent effect on both HHV-6B
and HHV-7 replication. Similarly, IFA analysis of HCMV
infection (Fig. 6) shows that U94/REP treatment severely
impairs virus replication, inhibiting expression of IE antigens
(IE-1 and 2), early (ppUL44, not shown) and late proteins
(pp65 and gB).
Discussion
The genome of HHV-6 encodes U94/rep, a gene absent in
all other members of the human herpesvirus family, with a
striking homology to the AAV-2 rep 68/78 gene. rep68/78
plays a pivotal role in AAV-2 replication (Berns and Giraud,
1996) as it is involved in AAV-2 DNA integration in the
infected cell genome, it is required for viral DNA replication,
and it modulates gene expression. Furthermore, it prevents
oncogenic transformation. HHV-6 U94/rep is more closely
related to AAV-2 rep than are the homologous proteins encoded
by other members of the parvovirus family (Thomson et al.,
1991) and possesses at least some of the functional properties
of the AAV-2 rep. In fact, HHV-6 U94/rep complements
replication of rep-deficient AAV-2 genomes (Thomson et al.,
1994), regulates gene expression (Araujo et al., 1995) and can
prevent oncogenic transformation (Araujo et al., 1995).
However, the precise function of U94/rep in HHV-6 biology
and replication is still largely undetermined. U94/REP can
regulate gene expression, as suggested by the observations that
it binds to single-stranded DNA (Dhepakson et al., 2002) and
to human transcription factors (Mori et al., 2000). It has been
suggested that U94/REP might be involved in viral latency. In
fact, U94/rep mRNA is detected in PBMCs of latently infected
normal donors (Rotola et al., 1998; Yoshikawa et al., 2003).
The potential involvement in viral latency is suggested also by
the fact that U94/rep expression in stably transformed cell lines
reduces HHV-6 DNA and RNA production (Rotola et al.,
1998) and that it inhibits replication of HHV-6 ‘‘amplicons’’
containing the HHV-6 origin of replication (Turner et al.,
2002).
Studies on the function of this unique gene have been
hindered by the lack of a convenient source of U94/REP. U94/
REP is expressed in HHV-6-infected cells only at low levels
(Rapp et al., 2000), and although high expression can be
obtained by in vitro transcription–translation, a range of
truncated forms are produced (Gompels, unpublished results);
furthermore, transformed eukaryotic cell lines transcribing the
U94/rep gene were easily obtained, but it has not been possible
to produce and purify the protein, due to the low levels of
expression (Rotola et al., 1998; Caselli and Di Luca,
unpublished). Previous reports were obtained transfecting the
U94/rep gene or producing a fusion protein (Mori et al., 2000;
Rapp et al., 2000; Rotola et al., 1998; Thomson et al., 1994;
Turner et al., 2002). Instead, we have produced in E. coli and
purified the full-length U94/REP protein. The purified protein
E. Caselli et al. / Virology 346 (2006) 402–414 409reacts specifically in ELISA and immunoblotting with a
polyclonal anti-U94/REP rabbit serum obtained by DNA
immunization. The short poly-(His) sequence present in the
fusion protein does not affect serological detection; therefore, it
was not necessary to remove this tail after purification. The
specific reactivity observed in Western blots was confirmed
using human sera from HHV-6-positive individuals (Caselli et
al., 2002), suggesting that the protein is immunogenic and is
expressed during in vivo infection.
Here, the biological effect of U94/REP was studied by
incubating infected cells in medium containing the recombi-
nant protein. Exogenous U94/REP is internalized by human
cells and targets specifically to the nucleus (Fig. 2), in
accordance with its possible role in DNA replication and
expression. U94/REP has no effect on viral entry but inhibits
significantly HHV-6 production (Fig. 3), and the block takes
place before DNA replication, as shown by semiquantitation of
viral DNA and IE/E mRNAs. The function of U94/REP is
dependent on the protein conformation, being abolished by
heat denaturation, and is mediated by single-strand DNA-
binding activity (Figs. 4A, B). Most likely, the active domain is
contained in the N-terminal fragment, as shown by the lack of
activity of the C-terminus.
Interestingly, the inhibitory effect of U94/REP is not limited
to HHV-6 but extends to the other human betaherpesviruses
HCMV and HHV-7. Also in the case of HCMV, the inhibition
takes place at an early stage of replication. Furthermore, during
the immediate-early phases of infection, the matrix protein
encoded by UL83 (pp65) localizes in the nucleus as a
component of viral inoculum, and, after DNA replication, it
is present mostly in the cytoplasm. In the presence of U94/REP,
pp65 was exclusively present in the nuclei of HCMV-infected
cells, suggesting that DNA replication was blocked (Fig. 6).
The activity of U94/REP is specific for betaherpesviruses, and
the alphaherpesvirus, HSV-1, replication is not affected. This is
also consistent with the observation that HHV-6 cannot
recognize the origin binding protein (OBP) sites required for
HSV replication, although it shares a similar strategy in
encoding an OBP (Inoue and Pellett, 1995). It is possible that
U94/REP has several targets. It inhibits the viral origin of DNA
replication, as shown by transient in vitro replication assays
(Turner et al., 2002), and this is further shown here with the
direct effect of U94/REP protein on virus replication which
correlates with its ssDNA-binding activity. It also represses
viral transcription, as shown by a significant reduction of viral
IE/E mRNAs. This could be mediated by interaction with
cellular factors, as in the case of AAV-2 rep68/78, that
downregulates AP-1-dependent transcription (Prasad et al.,
2003).
The inhibitory effect of U94/REP on viral replication
strengthens the notion that it might have a role in the
establishment and maintenance of viral latency, as originally
suggested by the detection of U94/rep transcripts in PBMCs of
latently infected healthy adults (Rotola et al., 1998). Further-
more, high levels of antibody to U94/REP have been detected
in some multiple sclerosis patients, suggesting differences in
latency regulation, though this could be contributed byunderlying immune defects in these patients (Caselli et al.,
2002). As a general consideration, the latency of herpesviruses
does not depend on the presence of rep homologues, and,
among the many herpesviruses so far characterized, only 2
betaherpesviruses, HHV-6 and the rat cytomegalovirus
(RCMV), encode a rep homologue, with similar genomic
position and orientation (Thomson et al., 1994; van Cleef et al.,
2004). However, the RCMV rep (r127) is dispensable for virus
replication and has no significant effect on virus production,
although effects on latency were not examined (van Cleef et al.,
2004). Interestingly, RCMV r127 is truncated at the N-
terminus, and the inhibitory activity of HHV-6 U94/REP
resides in the N-terminus. Furthermore, RCMV rep r127 differs
from HHV-6 U94/REP in that it has broad DNA-binding
activity to both ss and dsDNA binding, whereas U94/REP is
specifically an ssDNA-binding protein (Dhepakson et al.,
2002). Of note, AAV rep which shares sequence similarity
with HHV-6 rep can be complemented by HHV-6 U94/rep and
also can inhibit herpesvirus DNA replication using a domain
which maps to the N-terminus (Kleinschmidt et al., 1995;
Thomson et al., 1994). It has also been shown that HHV-6
latency is characterized by a transcription pattern similar to that
of HCMV, with transcripts from the E1/E2 regions (Kondo et
al., 2002). Therefore, it is possible that HHV-6 latency does not
depend exclusively on U94/rep. Nevertheless, U94/rep is
highly conserved in HHV-6 variants, is transcribed in latently
infected PBMCs and inhibits betaherpesviruses replication.
These observations point to a specific role for U94/REP in the
regulation of virus production and, combined with the
observation that co-reactivations of betaherpesviruses are
frequent in immunosuppressed patients, suggest that it might
be an interesting candidate for the development of new
antiviral agents specific for betaherpesviruses.
The origin of rep genes in HHV-6 and RCMV is completely
unknown. HHV-6 U94/rep appears to have a different
evolutionary conserved role from RCMV rep as in HHV-6
strains U94/rep genes are highly conserved whereas RCMV rep
is absent in some RCMV strains (Voigt et al., 2005). However,
the rep genes in HHV-6 and RCMV have similar genomic
locations and orientations, suggesting that they might have
diverged from a common origin. This suggests that an ancestral
parvovirus may have integrated in the genome of a betaher-
pesvirus progenitor during coinfection and rep sequences were
lost after phylogenetic divergence, except when they developed
a novel function in the herpesviral host (van Cleef et al., 2004).
Moreover, in the case of the closely related HHV-6 and HHV-7,
the fact that HHV-7 can replicate the HHV-6 ori in trans
replication assays but HHV-6 cannot replicate the HHV-7 ori
while HHV-7 which lacks U94/rep can reactivate HHV-6
(Katsafanas et al., 1996) may also point to a role here of the
HHV-6 replication inhibitor U94/REP in the regulation of
replication and latency (Steeper et al., 1990; van Loon et al.,
1997). Thus, in the case of HHV-6, the novel functions gained
might be represented by a tight control of latency and a
reduction of viral replication, possibly leading to the natural
selection of less virulent strains to favor long-term survival in
the host.
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Viruses and cells
Cell-free virus inocula were obtained as previously de-
scribed: HHV-6 variant A (strain U1102) was grown and
analyzed in the J-Jhan cell line (Rotola et al., 1998); HHV-6
variant B (strain Z29) and HHV-7 (strain CZ; Portolani et al.,
1995) were grown and analyzed in the Sup T1 cell line
(Menegazzi et al., 1999); HSV-1 (strain F) was grown and
analyzed in the epithelial Vero and in the T lymphoid J-Jhan
cell lines (Caselli et al., 2000). HCMV (Towne strain) was
grown on human embryonic lung fibroblasts (HEL; Nakamura
et al., 1988).
Both T lymphoid J-Jhan and Sup T1 cell lines were grown
in suspension in RPMI 1640 supplemented with 10% fetal calf
serum (FCS). Adherent Vero and HEL cells were respectively
cultured in DMEM and MEM supplemented with 10% FCS.
Plasmids construction
The full-length U94/rep gene was obtained by PCR
amplification of ORF U94 of HHV-6 variant B, as previously
described (Rotola et al., 1998). The U94/rep gene from HHV-
6B R1 strain (Dewhurst et al., 1992), cloned in the pSR2PH
vector, was excised by HindIII digestion and subcloned into
bacterial pQE30 vector (Qiagen), obtaining the recombinant
plasmid pQE-rep. The gene was cloned in frame with a stretch
of six histidine residues (His)6 at the amino-terminus, under the
control of a T5 promoter/lac operator. The recombinant
plasmid was used to transform the strain M15 of E. coli host
cells, harboring the pREP4 plasmid, which contains the lacI
gene coding for lac repressor. Two other plasmids were
constructed, containing the amino-terminal (RepN) and the
carboxy-terminal (RepC) regions of U94/rep gene. These
regions were obtained by PstI and EcoRV–HindIII digestion
of pSR2PH vector, resulting in two fragments of 978 bp and
813 bp which were subcloned in pQE30 vector.
Upon addition of isopropylthiogalactoside (IPTG), the T5/
lac promoter is activated, resulting in high yield production of
the fusion proteins cloned in pQE30.
Production and purification of U94/REP protein
Bacterial M15 host cells transformed with plasmid pQE-rep
were grown at 37 -C in LB medium containing 100 Ag/ml
ampicillin and 50 Ag/ml kanamycin up to OD660nm = 0.4–0.6
and subsequently induced with 2 mM IPTG. After 1, 3 and 5
h of induction at 37 -C, samples were collected by centrifu-
gation and analyzed for the presence of the recombinant
proteins. Cell pellets from 500 ml culture were suspended in 50
ml lysis buffer (50 mM Tris–HCl pH 8, 2 mM EDTA, 1 mM
DTT, 1 Ag/ml aprotinin, 1 mM PMSF, 100 Ag/ml lysozyme and
1% Triton X-100). After incubation for 30 min at room
temperature, the suspension was cleared by sonication (three
cycles of 15 s with a 15 s interval) and centrifuged in a
microfuge for 15 min at 13,000 rpm at 4 -C. Samples fromsupernatant (soluble fraction), pellet (insoluble fraction) and
total lysate were analyzed by SDS-PAGE. U94/REP protein
was recovered mostly from the insoluble fraction, thus samples
were solubilized in lysis buffer containing increasing molar
concentration of urea (2, 4, 6, 8 M). Each fraction was analyzed
in SDS-PAGE and Western blot. Complete solubilization of the
protein was achieved with lysis buffer supplemented with 6 M
urea. The fraction containing the recombinant protein was
dialyzed to eliminate residues of Triton X-100 and purified
under denaturing conditions by hydroxyapatite chromatogra-
phy, using lysis buffer in a phosphate gradient. The sample was
applied to the column after equilibration with lysis buffer
without Triton, pH 6.8. The resin was washed with a 10–200
mM sodium phosphate buffer, and the protein was eluted with
500 mM phosphate buffer. Each fraction was examined by
spectroscopy at 280 nm and subsequently analyzed by SDS-
PAGE and Western blot. Endotoxin levels were tested and were
below 0.5 EU/Ag protein in all assays performed. The same
procedure was applied to obtain RepN and RepC protein
fragments, resulting in two peptides of 35.8 and 29.8 kDa
respectively. Mock preparations were obtained from M15 E.
coli cells transformed with the pQE30 vector alone, extracted
as described for pQE-rep transformed cells. Briefly, cells were
cultured for 5 h in the presence of 2 mM IPTG, then extracted
and solubilized with lysis buffer containing 6 M urea, and
finally refolded in aqueous buffer. Mock lysate was used at the
same protein concentration as purified U94/REP protein.
Production of polyclonal anti-U94/REP serum
To obtain a specific anti-U94/REP serum, rabbits were
immunized by DNA vaccination, using as immunogen the
plasmid pSR2PH, containing HHV-6 U94/rep. Plasmid DNA
was prepared as previously described (Caselli et al., 1999,
2000) and suspended 1 mg/ml in sterile phosphate buffer (PBS;
137 mM NaCl, 3 mM KCl, 80 mM Na2HPO4, 1 mM
NaH2PO4, pH 7.4). Animals were injected with 300 Ag of
pSR2PH DNA by intramuscular route and subsequently
boosted (with 2-week intervals) with the same dose of DNA,
once subcutaneously and twice intradermally in the ear pinna.
One week before intramuscular immunization, animals were
injected with 100 Al of 0.5% bupivacaine solution, with the aim
to increase antigen capture and expression at the site of DNA
injection (Caselli et al., 1999, 2000). Blood was collected from
the ear vein before (pre-immune control serum) and after
(immune serum) immunizations. Serum was obtained by
centrifugation of coagulated blood and used in Western blot
assay and ELISA to determine the presence and identity of
U94/REP protein.
Western blot assay and ELISA
To assess the identity of the recombinant U94/REP protein,
specific Western blot and ELISA were developed. The rabbit
antiserum obtained by DNA immunization was utilized as the
primary antibody. Briefly, for Western blot, the same amount of
U94/REP protein, RepN and RepC protein subfragments or
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SDS-PAGE and electrically transferred onto nitrocellulose
paper with transfer buffer (25 mM Tris, 192 mM glycine and
20% methanol). Blots were incubated 1.5 h in a saturation
buffer consisting of 5% dehydrated non-fat milk in TBS (10
mM Tris–HCl, pH 7.4, 150 mM NaCl). After three washings
of 10 min each with TBS containing 0.5% Tween 20 (TBS-T),
nitrocellulose filters were incubated for 1 h in fresh TBS-T
containing 5% dehydrated milk and the rabbit polyclonal
antiserum diluted 1:200. Following three additional washings
in TBS-T, blots were incubated for 2 h with the appropriate
dilution of a horseradish-peroxidase (HRP)-labeled goat anti-
rabbit IgG (Roche Molecular Biochemicals) in TBS-T plus 5%
dehydrated milk. Blots were further washed three times with
TBS-T and then developed with the addition of a chemilumi-
nescent HRP substrate (SuperSignal West Pico Chemilumines-
cent Substrate, Pierce), according to the manufacturer’s
protocol.
For ELISA, immunoplates (Nunc) were coated overnight at
4 -C with 5 Ag/ml of purified recombinant U94/REP, or mock
lysate, suspended in 0.05 M sodium-bicarbonate buffer (pH
9.6). Excess of antigen was eliminated by three washings with
PBS containing 0.05% Tween 20 (PBS-T). A saturation step
was performed by incubating plates for 90 min at 37 -C with
200 Al/well of a PBS solution containing 10 mM CaCl2 and 5
mM MgCl2 (PBS-C) and 3% of bovine serum albumin (BSA;
Sigma). After three washings with PBS-T, 100 Al of the rabbit
antiserum obtained by DNA immunization, serially diluted in
saturation buffer (from 1:25 to 1:200), was added and tested in
duplicate. Pre-immune rabbit serum was used as negative
control. Incubation was performed for 90 min at 37 -C. Plates
were washed three times with PBS-T then 100 Al of
horseradish-peroxidase-labeled goat anti-rabbit IgG (Roche
Molecular Biochemicals), diluted 1:3000 in PBS-T plus 1%
BSA, was added to each well. Incubation was performed for 90
min at room temperature. Following three additional washings,
100 Al/well of ABTS substrate (Roche Molecular Biochem-
icals) was added for 45 min at room temperature. The
absorbance was measured at 405 nm. Absorbance values
higher than the mean control plus three standard deviations
(SD) were considered positive.
Analysis of U94/REP biological activity
The biological activity of recombinant U94/REP protein
was assayed by testing its effect upon the replication of
different herpesviruses in experiments of in vitro infection. For
HHV-6A, 107 J-Jhan cells were cultured for 24 h in complete
medium supplemented with 0, 1, 2 or 5 Ag/ml of recombinant
U94/REP or mock lysate (control) then centrifuged and
infected with a standardized amount of HHV-6A (strain
U1102) from a stock of 103 TCID50/ml, as previously
described (Rotola et al., 1998). Following 1 h of infection,
virus inoculum was removed, and cells were suspended in fresh
medium containing 0, 1, 2 or 5 Ag/ml of U94/REP or mock
lysate. Alternatively, the recombinant protein was added only
after the removal of virus inoculum. Cell samples werecollected at 0, 3, 7, 14, 21 and 28 days post-infection (p.i.)
and extracted as previously described for PCR and rtPCR
analyses (Menegazzi et al., 1999; Rotola et al., 1998). The
same experiments were also performed with equal amounts of
the RepN and RepC protein subfragments or with U94/REP
protein denatured by boiling at 100 -C for 10 min or U94/REP
preincubated for 30 min at 37 -C with 20 Ag/ml of calf thymus
single-stranded or double-stranded DNA (ssDNA or dsDNA;
Sigma).
HHV-6B and HHV-7 infections were performed on Sup T1
cells following the same procedure. For HCMV infection, viral
absorption was performed on 70–80% confluent monolayers
of HEL cells at a m.o.i. of 0.05 PFU/cell for 1 h, then virus
inoculum was removed and fresh medium containing 0, 1, 2 or
5 Ag/ml of U94/REP or mock lysate was added. Virus
production was evaluated 5 days after infection by immuno-
fluorescence assay.
HSV-1 infection was performed both in J-Jhan and in Vero
cells, using an m.o.i. of 0.01 and 0.001 PFU/cell. Briefly, 106 J-
Jhan cells or 5  105 Vero cells (seeded in 6-well plates) were
pre-treated for 24 h with U94/REP as described for HHV-6 and
infected with 0.01 or 0.001 PFU/cell of HSV-1 (strain F) for 1
h in PBS with 1% FCS. Virus inoculum was removed, and
fresh complete medium with 0, 1, 2 or 5 Ag/ml of U94/REP or
mock lysate was added. After 48 h of incubation, virus
production was evaluated by lysing cells and culture superna-
tant as described (Rotola et al., 1998) and titrating lysates on
Vero cells in the presence of 0.2% of gamma globulins.
U94/REP DNA-binding assay
The DNA-binding ability of U94/REP was evaluated by
DNA-affinity column chromatography. Briefly, 50 Ag of
recombinant protein was applied to a 0.5 ml column of
rehydrated ssDNA or dsDNA-cellulose (Sigma). After 1 h of
incubation at 4 -C, the resin was washed with 1 ml of buffer.
Aliquots of the input, flowthrough and wash fractions were
then analyzed by SDS-PAGE and Western blot.
PCR analyses
The presence and transcription of HHV-6A, HHV-6B and
HHV-7 in infected cells were analyzed by PCR and rtPCR
amplification of the following genes: U94, U42 and U31 for
HHV-6 A and B (Rotola et al., 1998) and U89/90, U42 and
U31 for HHV-7. PCR amplification was performed using
respectively 100 ng of total DNA or 200 ng total RNA
extracted from infected or uninfected cells. Amplification of
the house-keeping h-actin gene was used as a control.
Immunofluorescence assays
HHV-6 and HCMV infections were also analyzed by
specific immunofluorescence assays (IFA). For HHV-6, 105
cells were spotted onto glass slides and fixed by cold acetone
for 30 min at 20 -C. Slides were air-dried and kept at 20 -C
until use. For assay, slides were rehydrated by washings in
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directed against glycoprotein gp116 (late antigen) of HHV-6 A
and B (ABI, Columbia, MD, USA) diluted 1:100 in PBS for 35
min at 37 -C in a humidified chamber. Slides were washed
twice with PBS for 10 min, once for 1 min with tap water and
once for 1 min with distilled water, and incubated with
secondary antibody, FITC-conjugated goat-anti-mouse IgG
(Sigma, St. Louis, Missouri, USA) diluted 1:50 in PBS for
35 min at 37 -C. After washings as described, slides were
stained with 0.01% Evan’s Blue for 2 min, washed in distilled
water and finally mounted with 50% glycerol in PBS for
fluorescence microscope observation. For HCMV, infected
HEL cells were fixed 5 days after infection with cold
methanol–acetone (3:1) for 30 min at 20 -C, air-dried then
incubated for 1 h at 37 -C in a humid chamber with the
following primary mAbs diluted in PBS: anti-IE-A (clone E13)
and anti-pp65 (Clones 1C3+AYM-1; Argene BIOSOFT,
France), diluted 1:20; anti-ppUL44 (Clone 1202, Goodwin
Institute for Cancer Research, Plantation, Florida) diluted 1:
200; anti-gB, kindly obtained from M. Mach (Erlangen,
Germany), undiluted. A secondary FITC-conjugated Goat
anti-mouse antibody (Cappel, Organon Teknika Corp., Chester,
PA, USA) was used diluted 1:50.
Uptake and cellular localization of U94/REP protein was
analyzed by a specific IFA using an FITC conjugate mAb
directed against the stretch of six histidine residues (His)6
located at the amino-terminus of the recombinant protein
(Penta-His Alexa Fluor, FITC conjugate, Qiagen). J-Jhan cells
were cultured in complete RPMI medium containing 0, 1, 2 or
5 Ag/ml of U94/REP or mock lysate for 24 and 72 h. Cell
samples were washed twice in PBS, spotted onto glass slides,
fixed by 4% paraformaldehyde for 10 min and permeabilized
with 0.25% Triton X-100 in PBS for 5 min at room
temperature. U94/REP was revealed by incubation with the
anti-His mAb diluted 1:2000 in PBS plus 1% BSA at 4 -C
overnight. Slides were then washed four times in PBS and
mounted with 50% glycerol in PBS for microscope observa-
tion. All samples were observed under a UV light microscope
(Nikon Eclipse E600) equipped with a digital camera (DMX
1200).
Cytotoxicity assay
The toxicity of U94/REP recombinant protein on treated
cells was measured by the MTT assay. For suspension cultures,
cells were cultivated for 0, 3, 7, 14, 21 and 28 days in complete
medium containing 0, 1, 2 or 5 Ag/ml of U94/REP or mock
lysate. At the indicated time points, 105 cells per well were
seeded in a 96-well plate in 200 Al medium, incubated for 24
h and then supplemented with 25 Al/well of stock MTT
solution (5 mg/ml; Sigma). Cells were further incubated at 37
-C for 4 h, then the culture medium was carefully removed by
plate centrifugation, and 100 Al of DMSO was added to each
well for 1 h at 37 -C. The absorbance of samples was measured
at a wavelength of 570 nm with a microtiter plate reader. Each
assay was performed in triplicate. Adherent cells were directly
seeded in 96-well plates (104 cells per well in 200 Al volume)and incubated for 48 h with 0, 1, 2 or 5 Ag/ml of U94/REP or
mock lysate. After 48 h, cell samples were processed and
assayed as described for suspension cells.
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